Back to results
US 12,753,220 B2Granted
Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
AssigneeCellectis
InventorsCecile Schiffer-Mannioui, Philippe Duchateau
Life of this patent
Estimating the term…
Abstract
The present invention relates to engineered immune cells expressing new mesothelin (MLSN) specific chimeric antigen receptors (anti-mesothelin CAR) and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.
Claims17
A mesothelin specific chimeric antigen receptor (CAR) comprising at least:
- an extracellular ligand binding-domain comprising VH and VL from a monoclonal anti-mesothelin antibody;
- a transmembrane domain;
- and
- a cytoplasmic domain comprising a CD3 zeta signalling domain and a co-stimulatory domain,
- wherein said extracellular ligand binding-domain is directed against the MSLN antigen polypeptide region SEQ ID NO:25,
- wherein said extracellular ligand binding-domain comprises:
- a variable heavy VH chain comprising CDRs from the antibody Meso1 having the amino acid sequence of SEQ ID NO:3 (CDRH1-Meso1), SEQ ID NO:4 (CDRH2-Meso1) and SEQ ID NO:5 (CDRH3-Meso1), and
- a variable heavy VL chain comprising CDRs from the antibody Meso1 having the amino acid sequence of SEQ ID NO:6 (CDRL1-Meso1), SEQ ID NO:7 (CDRL2-Meso1) and SEQ ID NO:8 (CDRL3-Meso1).
5 more elements
An engineered immune cell expressing at the cell surface membrane a mesothelin specific chimeric antigen receptor comprising at least:
- an extracellular ligand binding-domain comprising VH and VL from a monoclonal anti-mesothelin antibody;
- a transmembrane domain;
- and
- a cytoplasmic domain comprising a CD3 zeta signalling domain and a co-stimulatory domain,
- wherein said extracellular ligand binding-domain is directed against the MSLN antigen polypeptide region SEQ ID NO:25,
- wherein said extracellular ligand binding-domain comprises:
- a variable heavy VH chain comprising CDRs from the antibody Meso1 having the amino acid sequence of SEQ ID NO:3 (CDRH1-Meso1), SEQ ID NO:4 (CDRH2-Meso1) and SEQ ID NO:5 (CDRH3-Meso1), and
- a variable heavy VL chain comprising CDRs from the antibody Meso1 having the amino acid sequence of SEQ ID NO:6 (CDRL1-Meso1), SEQ ID NO:7 (CDRL2-Meso1) and SEQ ID NO:8 (CDRL3-Meso1).
5 more elements
Dependencies are inferred from the claim text.